Melanie Jane Calvert | |
|---|---|
| Alma mater | University of Birmingham |
| Scientific career | |
| Institutions | University of Birmingham |
| Thesis | The interactions of cardiac and skeletal troponin I and troponin C (2000) |
Melanie Jane Calvert is a British epidemiologist who is professor of Outcomes Methodology at the University of Birmingham. Her research considers the design of clinical trials. She is Director of the Centre for Patient-reported outcomes Research, which looks to enhance patient care through optimised use of PROs in clinical trials. She was elected Fellow of the Academy of Medical Sciences in 2025.
Calvert studied biochemistry at the University of Birmingham. [1] She remained in Birmingham for her graduate studies, where she was supported by a Wellcome Trust prize[ citation needed ] to study the interactions of cardiac and skeletal troponins. [2]
In 2024, Calvert was awarded an National Institute for Health and Care Research senior investigator award. [3] Her research looks to improve patient-reported outcomes (PROs), and advocates for patient concerns to inform regulatory decision making. [4] She is Director of the Centre for PROs Research, which looks to improve patient outcomes and centre patient perspectives at the heart of health research. [5] She established a UK-wide network that looked to regulate and understand public perspectives of advanced therapies. [6] [4] For example, the network supports companies to develop, trial and launch cell and gene therapies. [4] Calvert worked with George Freeman on the Taskforce on Innovation, Growth and Regulatory Reform (TIGRR) Report, which considered the regulation of medical devices. [7] Calvert studied long COVID, [8] analysing the financial impact, evaluating how people of different ethnicities suffered from the condition, [9] and developing strategies (including a questionnaire [10] ) to measure the outcomes of long COVID therapies.
Calvert was elected a Fellow of the Academy of Medical Sciences (United Kingdom) in 2025. [6]